Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03 2022 - 4:01PM
Business Wire
Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the
development of medicines that control the expression of genes,
today announced the grant of restricted stock unit (RSU) awards for
an aggregate of 77,850 shares of Syros common stock to four newly
hired employees in connection with their commencement of employment
with Syros. These RSUs were granted as material inducements to
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs were granted on May 31, 2022, vest as to one-quarter of
the shares on May 31, 2023 and as to an additional one quarter of
the shares at the end of each successive year thereafter subject to
the employee’s continued service with Syros, and are subject to the
terms and conditions of a restricted stock unit agreement covering
the award and Syros’ 2022 Inducement Stock Incentive Plan.
About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the
expression of genes. Based on its unique ability to elucidate
regulatory regions of the genome, Syros aims to develop medicines
that provide a profound benefit for patients with diseases that
have eluded other genomics-based approaches. Syros is advancing a
robust clinical-stage pipeline, including: tamibarotene, a
first-in-class oral selective RARα agonist in RARA-positive
patients with higher-risk myelodysplastic syndrome and acute
myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in
patients with acute promyelocytic leukemia; and SY-5609, a highly
selective and potent oral CDK7 inhibitor in patients with select
solid tumors. Syros also has multiple preclinical and discovery
programs in oncology and monogenic diseases. For more information,
visit www.syros.com and follow us on Twitter (@SyrosPharma) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220603005019/en/
Media Contact Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com Investor Contact Hannah Deresiewicz
Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024